CDK4 and breast carcinoma: In addition, abemaciclib and palbociclib treatment have been shown to downregulate mTOR signaling in small cell lung and breast cancer (Naz et al., 2018; Maskey et al., 2021), providing support that CDK4/6 inhibitors may induce reversible senescence through downregulating mTOR signaling.